Transplant Infectious Disease最新文献

{"title":"Cytomegalovirus DNA Doubling Time for Early Identification of Clinically Significant Infection Episodes in Allogeneic Hematopoietic Stem Cell Transplant Recipients Undergoing Primary Letermovir Prophylaxis: A Multicenter Study.","authors":"Estela Giménez, Irene García Cadenas, José Luis Piñana, Eliseo Albert, Lourdes Vázquez, Alejandro Avendaño, Mónica Cabrero, Albert Esquirol, Rodrigo Martino, Javier López-Jiménez, María Ángeles Cuesta, Karem Humala, Sara Villar, Montserrat Rovira, Inmaculada Heras, Teresa Zudaire, Ignacio Arroyo, Amaya Zabalza, Beatriz Aguado, Carlos Solano, David Navarro","doi":"10.1111/tid.70080","DOIUrl":"https://doi.org/10.1111/tid.70080","url":null,"abstract":"<p><strong>Background: </strong>Letermovir (LMV) prophylaxis currently represents the first-line strategy for preventing clinically significant cytomegalovirus (CMV) infection (CsCMVi) in CMV-seropositive recipients of allogeneic hematopoietic stem cell transplantation (allo-HSCT). A wide variety of CMV DNA thresholds for LMV interruption and preemptive antiviral therapy (PET) inception are in place across transplantation centers.</p><p><strong>Methods: </strong>We evaluated the potential of CMV DNA doubling time (dt) in plasma to distinguish between CsCMVi and abortive CMV infection in allo-HSCT recipients on primary LMV prophylaxis. Data from the Spanish Hematopoietic Transplantation and Cell Therapy Group multicenter registry included 296 allo-HSCT patients receiving LMV prophylaxis. Participating centers used a plasma CMV DNA threshold of ≥1000 IU/mL for initiating PET. The CMV DNA dt was calculated from the first two or three positive polymerase chain reaction (PCR) results based on pre-established criteria.</p><p><strong>Results: </strong>CMV DNAemia developed in 64 recipients (21.6%) with a total of 88 episodes, of which CsCMVi occurred in 9 recipients (3.04%) and included 10 episodes (one patient had confirmed CMV gastrointestinal disease). A non-calculable CMV DNA dt had a negative predictive value of 94% for CsCMVi. For initial episodes with calculable CMV DNA dts (4/7 CsCMVi and 8/57 no-CsCMVi), a threshold of >2.35 days had a specificity of 100% for ruling out CsCMVi.</p><p><strong>Conclusion: </strong>CMV DNA dt could optimize CMV infection management in allo-HSCT patients under LMV prophylaxis, independent of the PCR platform used.</p>","PeriodicalId":23318,"journal":{"name":"Transplant Infectious Disease","volume":" ","pages":"e70080"},"PeriodicalIF":2.6,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144660366","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pure Red Cell Aplasia and C3-Dominant Glomerulonephritis Secondary to Parvovirus B19 in Post Kidney Transplantation Patient: A Case Report.","authors":"Sirihatai Konwai, Supawas Thawornkaew, Chanyanuch Rakpithayanon, Natavudh Townamchai, Jerasit Surintrspanont, Nichthida Tangnuntachai, Noppacharn Uaprasert, Jakapat Vanichanan, Kearkiat Praditpornsilpa, Yingyos Avihingsanon, Suwasin Udomkarnjananun, Thunyatorn Wuttiputhanun","doi":"10.1111/tid.70081","DOIUrl":"https://doi.org/10.1111/tid.70081","url":null,"abstract":"","PeriodicalId":23318,"journal":{"name":"Transplant Infectious Disease","volume":" ","pages":"e70081"},"PeriodicalIF":2.6,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144660368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Current Practice Patterns and Educational Needs of the ESCMID Study Group for Infections in Compromised Hots.","authors":"Maddalena Giannella, Daniele Riccucci, Renato Pascale, Elisa Cordero, Nicolas J Mueller, Monica Slavin, Michael Ison","doi":"10.1111/tid.70076","DOIUrl":"https://doi.org/10.1111/tid.70076","url":null,"abstract":"<p><strong>Background: </strong>The ESCMID Study Group for Infection in Compromised Hosts (ESGICH) conducted a survey to assess its members' demographics, clinical focus, training pathways, research activities, and educational needs. The primary objective was identifying the current expertise and challenges professionals face in immunocompromised host infectious diseases (ICH-ID) and determining how ESGICH can better support their clinical and research endeavors.</p><p><strong>Methods: </strong>A structured questionnaire was distributed to ESGICH members by email and was posted on X to collect information on work settings, patient populations, training, collaborative networks, research involvement, and educational experiences. The survey also assessed interest in future educational initiatives, including certification programs and targeted training opportunities.</p><p><strong>Results: </strong>Overall, 119 colleagues participated in the survey, with the majority being members of ESGICH, which had approximately 230 participants, yielding a response rate of 52%. Most of the respondents were from Europe and noted significant involvement in ICH-ID clinical care and research. Many respondents provide care for transplant recipients and haemato-oncology patients, with varying levels of institutional support, and often had clinical responsibility beyond the ICH-ID population. Training in ICH-ID is inconsistent, with many participants expressing a need for more structured training pathways. Research engagement was high, though support structures varied. Participants identified key educational gaps and expressed interest in webinars, in-person meetings, and certification programs.</p><p><strong>Conclusion: </strong>The findings highlight the need for ESGICH to enhance educational opportunities, strengthen research networks, and advocate for standardized ICH-ID training. Addressing these gaps will improve professional development and ultimately enhance patient care for ICHs.</p>","PeriodicalId":23318,"journal":{"name":"Transplant Infectious Disease","volume":" ","pages":"e70076"},"PeriodicalIF":2.6,"publicationDate":"2025-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144584975","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic Impact of Cytomegalovirus Reactivation After Transplantation From Cord Blood Compared to Other Donor Sources in Patients With Adult T-Cell Leukemia/Lymphoma in the Pre-Letermovir Era.","authors":"Takuya Fukushima, Hidehiro Itonaga, Hikaru Sakamoto, Wataru Takeda, Masahito Tokunaga, Takeharu Kato, Takuro Kuriyama, Toshiro Kawakita, Machiko Fujioka, Yasuhiko Miyazaki, Naoyuki Uchida, Yasuo Mori, Hirohisa Nakamae, Masao Ogata, Kazunori Imada, Makoto Onizuka, Kazuho Morichika, Yoshinobu Kanda, Takahiro Fukuda, Yoshiko Atsuta, Shigeo Fuji, Makoto Yoshimitsu","doi":"10.1111/tid.70070","DOIUrl":"https://doi.org/10.1111/tid.70070","url":null,"abstract":"<p><strong>Background: </strong>Cytomegalovirus reactivation (CMV-react) is an indicator for the worse non-relapse mortality (NRM) and overall survival (OS) after allogeneic hematopoietic stem cell transplantation using HLA-matched related donor (MRD) and unrelated donor (URD) for adult T-cell leukemia/lymphoma (ATL). However, it remains unclear whether CMV-react correlates with outcomes after unrelated cord blood (U-CB) transplantation.</p><p><strong>Methods: </strong>We conducted a retrospective nationwide study to evaluate the impact of CMV-react on the outcomes after posttransplant 100 days. Data were collected from 205, 461, and 268 patients who used MRD, URD, and U-CB, respectively, between 2001 and 2022 and survived without relapse for over 100 days after transplantation.</p><p><strong>Results: </strong>In multivariate analyses, CMV-react correlated with worse OS in the MRD (hazard ratio [HR], 1.56; 95% confidence interval [CI], 1.02-2.39; p = 0.04) and URD groups (HR, 1.45; 95% CI, 1.00-2.09; p = 0.05), but not in the U-CB group (HR, 1.34; 95% CI, 0.88-2.03; p = 0.2). CMV-react correlated with higher NRM in the MRD (HR, 1.79; 95% CI, 1.01-3.16; p = 0.05) and URD groups (HR, 1.68; 95% CI, 1.01-2.82; p = 0.05), but not in the U-CB group (HR, 1.16; 95% CI, 0.62-2.19; p = 0.6). CMV-react did not correlate with the incidence of relapse in any group.</p><p><strong>Conclusion: </strong>CMV-react was not associated with the outcomes in the U-CB group, while CMV-react correlates with worse OS and NRM in the MRD and URD groups, indicating the need for a more intensive strategy for late-phase complications in U-CB transplantation for ATL with and without CMV-react.</p>","PeriodicalId":23318,"journal":{"name":"Transplant Infectious Disease","volume":" ","pages":"e70070"},"PeriodicalIF":2.6,"publicationDate":"2025-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144584905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Invasive Fungal Disease in Solid Organ and Hematopoietic Cell Transplant Recipients, United States.","authors":"Jeremy A W Gold, Kaitlin Benedict, Elizabeth Sajewski, Tom Chiller, Meghan Lyman, Mitsuru Toda, Jessica S Little, Luis Ostrosky-Zeichner","doi":"10.1111/tid.70077","DOIUrl":"10.1111/tid.70077","url":null,"abstract":"<p><strong>Background: </strong>Updated benchmark data on invasive fungal disease (IFD) in solid organ transplantation (SOT) and hematopoietic cell transplantation (HCT) recipients are necessary to increase clinical recognition and inform treatment and prevention strategies. We estimated IFD incidence and potential risk factors in transplant recipients in a large US commercial health insurance database.</p><p><strong>Methods: </strong>We observed patients who received SOT or HCT during 2018-2022 until IFD development, disenrollment, or database end date (July 31, 2023). We calculated incidence (per 1000 person-years) and time to IFD development, comparing demographic features and underlying conditions for IFD versus non-IFD patients.</p><p><strong>Results: </strong>Overall, 9143 patients received an SOT (5667 kidney, 2025 liver, 759 heart, 650 lung, 39 pancreas, 3 intestine), and 5693 patients received an HCT (3519 autologous, 2114 allogeneic, 60 unspecified type). Among SOT patients, 360 developed an IFD (incidence: 21.0 [per 1000 person-years]). Mold infections had the highest incidence (7.1), followed by unspecified mycoses (3.9) and endemic mycoses (3.3). Among HCT patients, 292 developed an IFD (incidence: 28.5), with higher incidence among allogeneic (58.4) versus autologous (12.8) HCT recipients; among all HCT recipients, unspecified mycoses had the highest incidence (8.3), then pneumocystosis (7.6), and mold infections (6.7). Median time to IFD was 173.5 days for SOT recipients and 197.5 days for HCT recipients. IFD risk varied substantially by transplant type, region, and certain underlying conditions.</p><p><strong>Conclusion: </strong>Our results suggest that IFDs remain an important cause of infection among SOT and HCT recipients, particularly later in the posttransplant period, and highlight the need for prevention strategies.</p>","PeriodicalId":23318,"journal":{"name":"Transplant Infectious Disease","volume":" ","pages":"e70077"},"PeriodicalIF":2.6,"publicationDate":"2025-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12289323/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144584977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dengue Fever in Heart Transplant Recipients: A Latin American Experience During Recent Epidemic Years.","authors":"Laura Caroline Tavares Hastenteufel, Fernanda Lourega Chieza, Letícia Orlandin, Ana Clara Jaeger, Marcelle Duarte Alves, Nadine Clausell, Lívia Adams Goldraich","doi":"10.1111/tid.70073","DOIUrl":"https://doi.org/10.1111/tid.70073","url":null,"abstract":"","PeriodicalId":23318,"journal":{"name":"Transplant Infectious Disease","volume":" ","pages":"e70073"},"PeriodicalIF":2.6,"publicationDate":"2025-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144584976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real World Efficacy and Safety of Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Liver Transplant Recipients.","authors":"Erdem Bektas, Aysenur Yilmaz, Cevat Ilteris Kikili, Kanan Nuriyev, Zulal Istemihan, Ibrahim Volkan Senkal, Ziya Imanov, Bilger Cavus, Asli Cifcibasi Ormeci, Filiz Akyuz, Kadir Demir, Selman Fatih Besisik, Sabahattin Kaymakoglu","doi":"10.1111/tid.70068","DOIUrl":"https://doi.org/10.1111/tid.70068","url":null,"abstract":"<p><strong>Background: </strong>The efficacy and safety of nucleos(t)ide analogs is currently a critical issue in the treatment of hepatitis B virus infection. We aimed to investigate the long-term efficacy and safety profile of tenofovir alafenamide (TAF) treatment in the liver transplant recipients (LTRs).</p><p><strong>Methods: </strong>This retrospective study was conducted with 72 LTRs who received TAF as sequential therapy after tenofovir disoproxil fumarate (TDF). The renal, metabolic outcomes, and efficacy of TAF were evaluated. In addition, some parameters were evaluated separately according to the use of calcineurin inhibitors.</p><p><strong>Results: </strong>Following TAF treatment, median serum phosphorus levels and estimated glomerular filtration rate (eGFR) increased significantly in the overall cohort (from 2.4 to 2.85 mg/dL [p < 0.001]; from 66 to 74 mL/min/1.73 m² [p = 0.028], respectively). These improvements were more pronounced in patients with baseline hypophosphatemia and reduced eGFR. However, no significant changes were observed in eGFR staging. A categorical worsening of lipid profile was noted based on the NCEP ATP-III criteria, with increases in some lipid parameters. No significant weight gain or increase in the incidence of posttransplant diabetes mellitus was observed. Antiviral efficacy was maintained following the switch from TDF to TAF. In addition, no significant changes in immunosuppressive drug dosing were required, and no adverse events related to TAF were reported.</p><p><strong>Conclusion: </strong>TAF was well-tolerated and effective in LTRs. The long-term benefits of TAF on hypophosphatemia, renal function, and effective viral suppression were demonstrated. The patients with an increased risk of cardiovascular disease should receive more intensive monitoring for changes in their lipid profile.</p>","PeriodicalId":23318,"journal":{"name":"Transplant Infectious Disease","volume":" ","pages":"e70068"},"PeriodicalIF":2.6,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144555062","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Longitudinal Innate and Heterologous Adaptive Immune Responses to SARS-CoV-2 JN.1 in Transplant Recipients With Prior Omicron Infection: Limited Neutralization but Robust CD4⁺ T-Cell Activity.","authors":"Victor H Ferreira, Brandon Keith, Faranak Mavandadnejad, Alejandro Ferro, Sara Marocco, Golnaz Amidpour, Alexandra Kurtesi, Freda Qi, Anne-Claude Gingras, Victoria G Hall, Deepali Kumar, Atul Humar","doi":"10.1111/tid.70067","DOIUrl":"https://doi.org/10.1111/tid.70067","url":null,"abstract":"<p><strong>Background: </strong>Solid organ transplant (SOT) recipients are at increased risk for severe COVID-19 and often exhibit reduced vaccine efficacy due to chronic immunosuppression. As new SARS-CoV-2 variants emerge, understanding immune responses following natural infection remains critical for informing protection strategies in this vulnerable population. We conducted a longitudinal study of SOT recipients who had recovered from Omicron BA.1 or BA.2 infection, evaluating immune responses to the JN.1 subvariant at 4-6 weeks and 1 year postinfection.</p><p><strong>Methods: </strong>Neutralizing antibodies to JN.1 were measured using a pseudovirus neutralization assay, and JN.1-specific T-cell responses were assessed by flow cytometry. Frequencies of bulk T-cells and innate immune cells, identified via flow cytometry, and their correlation with adaptive responses were also analyzed.</p><p><strong>Results: </strong>At 4-6 weeks, 30% of participants had detectable JN.1-neutralizing antibodies, rising to 43% at one year, although titers remained low. In contrast, CD4⁺ T-cell responses were robust and detected in 75%-83% of participants at 4-6 weeks, increasing to 75%-93% by 1 year. CD8⁺ T-cell responses were observed less frequently. Exploratory correlations between innate and bulk T-cell subsets with heterologous adaptive immune responses were investigated but did not reveal statistically significant relationships.</p><p><strong>Conclusion: </strong>These findings offer important insights into the durability and breadth of immunity following natural infection in immunocompromised transplant recipients. While heterologous neutralizing antibodies were limited, sustained CD4⁺ T-cell responses may help mitigate severe disease following exposure to JN.1-derived variants, which continue to dominate the SARS-CoV-2 landscape.</p>","PeriodicalId":23318,"journal":{"name":"Transplant Infectious Disease","volume":" ","pages":"e70067"},"PeriodicalIF":2.6,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144555060","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Measles and Solid Organ Transplantation: Diagnosis, Treatment, and Prevention.","authors":"Stephanie M Pouch, Akshatha Ravindra, Sara W Dong, Wanessa Trindade Clemente, Ricardo M La Hoz, Aaron Mishkin, Jonathan Hand, Maristela Pinheiro Freire, Jacques Simkins, Cameron Wolfe, John W Baddley","doi":"10.1111/tid.70066","DOIUrl":"https://doi.org/10.1111/tid.70066","url":null,"abstract":"<p><p>The recent international resurgence of measles has led to significant public health concerns and poses significant risks to immunocompromised patients, including those who have undergone solid organ transplantation (SOT). SOT recipients may present atypically and are at an increased risk of severe complications of measles infection, underscoring the importance of preventative measures. This review summarizes contemporary data regarding measles transmission, the clinical presentation, diagnosis, and treatment of SOT recipients, as well as strategies for measles prevention, infection control considerations, postexposure prophylaxis, and opportunities for the mitigation of donor-derived measles and measles vaccine viruses.</p>","PeriodicalId":23318,"journal":{"name":"Transplant Infectious Disease","volume":" ","pages":"e70066"},"PeriodicalIF":2.6,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144545003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Improving Vaccination Rates in Adult Solid Organ Transplant Candidates: Impact of an Infectious Diseases Pretransplant Clinic.","authors":"Zachary Hanna, Navina Birk, Joud Jarrah, Tommy Parraga, Jonathan Williams, Jennifer McCorquodale, Eloy E Ordaya, Odaliz Abreu-LanFranco, Ramon Del Busto, Mei Lu, Mayur Ramesh, George Alangaden","doi":"10.1111/tid.70059","DOIUrl":"https://doi.org/10.1111/tid.70059","url":null,"abstract":"<p><strong>Background: </strong>Despite guidelines recommending pretransplant immunizations for solid organ transplant candidates (SOTc), vaccine uptake is suboptimal. We evaluated the impact of an Infectious Disease Pretransplant (IDPT) clinic for improving vaccinations in SOTc.</p><p><strong>Methods: </strong>A retrospective quality improvement study of SOTc seen in the IDPT clinic between January 2020 and February 2021 at the Henry Ford Transplant Institute. Vaccination status before (pre-IDPT clinic visit) and 6 months after (post-IDPT clinic visit) were determined for influenza, pneumococcus, hepatitis B, hepatitis A, tetanus, and zoster vaccines. Differences in per-person year (PPY) vaccination rates and uptake of each vaccine type between the two time points were assessed. Factors associated with vaccine completion (at least one dose of six adult vaccines) in the post-IDPT clinic visit period were analyzed with logistic regression.</p><p><strong>Results: </strong>Of the 200 SOTc included, 60% were men. Vaccination rates were significantly higher in the post-IDPT clinic visit period; difference in median PPY vaccination rate was 0.61 (p < 0.001). Uptake was statistically significant for all six vaccine classes. A total of 29% patients completed vaccination. Increasing age was associated with likelihood of vaccine completion (odds ratio [OR], 1.14; 95% CI 1.08-1.21). Heart and lung transplant candidates had significantly higher odds of vaccine completion than kidney candidates after IDPT clinic visits (Heart: OR, 7.01; 95% CI 2.39-20.55) (Lung: OR, 10.76; 95% CI 3.56-32.55).</p><p><strong>Conclusion: </strong>IDPT clinic visits significantly increased vaccination rates in SOTc, especially in heart and lung transplant candidates. The IDPT clinic optimized vaccine completion for this highly vulnerable population.</p>","PeriodicalId":23318,"journal":{"name":"Transplant Infectious Disease","volume":" ","pages":"e70059"},"PeriodicalIF":2.6,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144545002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}